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Introduction
Synthetic biology has been defined, in a report by the Royal 
Academy of Engineering, as a discipline that aims to design and 
engineer biologically based parts, devices and systems [1]. It is a new 
but very rapidly growing field that has attracted considerable attention 
from researchers, governments and the public for its potential to 
change, quite profoundly, our relationship with the living world and 
our power to manipulate it [2-9]. The rise of this field has coincided 
closely with the emergence of regenerative medicine as a distinct 
discipline (Figure 1), both taking off rapidly in the early years of this 
century. In this article we argue that bringing these two young fields 
together, so that synthetic biology solutions are applied to problems of 
regeneration, has the potential to significantly enhance our ability to 
help those in clinical need.
Traditional efforts in regenerative medicine have always depended 
on using the natural, evolved behaviours of human cells. The earliest 
to be exploited were those concerned with wound healing and with 
tissue engraftment: together, these form the basis of reconstructive 
surgery, whether this is routine skin grafting or highly experimental 
transplantations of a hand or even a face (reviewed by [10]). From the 
middle of the last century, first researchers and then clinicians began 
to exploit an additional feature of the normal body, the ability of stem 
cells to regenerate missing tissue. Use of stem cells from bone marrow 
to reconstitute the haematopoietic system was achieved in the 1950s 
in both rodents [11] and humans [12]: it has since become a relatively 
routine procedure following treatment for leukaemia or following 
accidental exposure to ionizing radiation. This century, the range of 
stem cell treatments has expanded greatly, at least in the experimental 
phase, and includes treatment with a variety of stem cells (including 
mesenchymal, perivascular, endothelial, neuronal, embryonic and 
limbal) with the aim of treating diseases such as diabetes, paraplegia, 
ataxia, multiple sclerosis, and heart failure (reviewed in [13]). So far, 
the clinical outcomes of most early trials have been disappointing, 
although the increasing commitment of industry to exploring this field 
suggests that optimism is far from lost. In all cases, though, the aim has 
been to use the natural abilities of cells to make trophic factors and to 
produce new tissues as they would in normal development and tissue 
maintenance.
An even more recent development has been the idea of engineering 
‘scaffolds’, either wholly artificial or made by manipulation of natural 
molecules or mixtures of artificial and natural molecules, to guide 
cells to make tissues with specific shapes [14]. Examples include 
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Abstract
Synthetic biology uses interchangeable and standardized “bio-parts” to construct complex genetic networks that 
include sensing, information processing and effector modules: these allow robust and tunable transgene expression 
in response to a change in signal input. The rise of this field has coincided closely with the emergence of regenerative 
medicine as a distinct discipline. Unlike synthetic biology, regenerative medicine uses the natural abilities of cells 
to make trophic factors and to produce new tissues as they would in normal development and tissue maintenance. 
In this article, we argue that bringing these young fields together, so that synthetic biology techniques are applied 
to the problem of regeneration, has the potential significantly to enhance our ability to help those in clinical need. 
We first review the synthetic tool kit available for engineered mammalian networks, then examine the main areas in 
which synthetic biology techniques might be applied to promote regeneration: (i) biosynthesis and controlled release 
of therapeutic molecules, (ii) synthesis of scaffold material, (iii) regulation of stem cells, and (iv) programming cells to 
organize themselves into novel tissues. We finally consider the long-term potential of synthetic biology for regenerative 
medicine, and the risks and challenges ahead.
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Figure 1: The rise of synthetic biology and regenerative medicine. Regenera-
tive medicine is shown in blue and synthetic biology, taking off later but now 
with a similar trajectory, in red. The green line shows publications for laser 
surgery, chosen as a ‘control’ for the general gentle rise in medical publica-
tion. This graph was obtained by performing a PubMed search using the term 
XXXX NNNN, where XXXX was “synthetic biology”, “regenerative medicine” 
or “laser surgery” and NNNN was each year in the range 1980-2010.
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the formation of a collagen pattern in the shape of a human nipple 
[15], the formation of functional heart valves [16], reconstruction of 
cartilage [17], bone [18], oesophagus [19] and bladder wall [20]. In 
a variation on that theme, the engineering of structures that already 
incorporate cells in situ has been used to produce functional heart 
tissue [21]. Natural, de-cellularized scaffolds obtained by detergent-
washing matrices of natural organs have also been used successfully 
for tissue engineering [22]. The possibility of engineering a matrix that 
has a shape different from that of any natural tissue (for example, for 
reconstruction of a body altered by accident or congenital abnormality) 
allows some creativity, but the actions of the cells themselves are still 
controlled by their evolved ‘developmental programmes’. This fact 
imposes a significant limitation on the scope of conventional tissue 
engineering. It is in liberating the field from this limitation that the 
potential of synthetic biology lies.
Synthetic biology differs from traditional ‘genetic engineering’ in 
several ways. First, it tends to involve not just the manipulation of one 
gene but the construction of complex, larger-scale genetic systems. 
Second, most of its practitioners stress an ‘engineering approach’ using 
standard components and modules as m ble: effectively a move from a 
‘craft’ phase towards an ‘industrial’ phase of biological engineering [23]. 
With the design and construction of complex modular systems from 
well-characterized parts, a wide range of new applications becomes 
available, as illustrated by the use of new terms such as ‘synthetic 
tissue biology’ [24], ‘synthetic morphology’ [25] and ‘synthetic 
toxicology’ [26]. As in other fields, the potential inputs of synthetic 
biology to regenerative medicine can be of two kinds: the first aiding 
understanding and the second directly aiding a patient. Through de 
novo design, synthetic biology can help elucidate cellular mechanisms 
and pathways: engineering entirely or partially synthetic genetic 
networks in living cells gives us clues as to how natural systems are 
assembled and how they operate in organisms [27]. Through rational 
design based on this knowledge, synthetic biology has the potential 
to create new systems for diagnosis or treatment. In particular, it has 
enormous potential for tissue engineering and regenerative medicine 
in general.
In this review, we will provide an overview of some possible 
applications of synthetic biology to regenerative medicine. We will 
detail the synthetic tool kit already available for engineered mammalian 
networks, then review the first, tentative steps that have been made 
in applying synthetic biology to tissue engineering and to stem cell 
biology. We finally consider the long-term potential of synthetic 
biology for regenerative medicine, and the risks and challenges ahead.
Areas for application of synthetic biology techniques
There are four main areas in which the techniques of synthetic 
biology might be applied to promote regeneration;
•	 Biosynthesis and controlled release of therapeutic molecules
•	 Synthesis of scaffold material
•	 Regulation of stem cells
•	 Programming cells to organize themselves into novel tissues.
The rest of this chapter will first describe existing tools of synthetic 
biology that might be useful in all of these areas, and will then consider 
how they might be applied to each area in turn.
Existing components for mammalian synthetic biology
Most synthetic biology is based on the use of interchangeable and 
standardized ‘bio-parts’. These are epitomized by the rapidly-growing 
collection of ‘Bio-Bricks’ made available to contestants in the annual 
iGEM competition [28], in which teams of undergraduates and even 
high school students compete to make ‘the best’ synthetic biological 
system. The parts are designed to be combined using standardized 
reactions, based mainly on restriction-ligation for prokaryotic systems 
and recombination-mediated cassette exchange for mammalian 
systems. Using these parts, complex genetic networks comprising 
sensing, information processing and effector modules can be (and 
have been) assembled through a systematic engineering approach not 
dissimilar, in principle, from the approaches used in the assembly of 
standard electronic components to make different circuits. The resulting 
synthetic systems allow robust and tunable transgene expression in 
response to changes in input signals. During the first wave of synthetic 
biology, around the turn of the century, bio-parts such as the toggle 
switch [29] and the oscillator [30] were developed in prokaryotes. Since 
2004, the scope of synthetic biology has been extended to mammalian 
cells (reviewed in [31-33]). Below is a non-exhaustive list of significant 
mammalian parts illustrated by some applications.
The synthetic tool kit
Synthetic Boolean logic gates (AND, OR, NOR, etc.) have been 
engineered in mammalian cells [34] where they regulate transgene 
expression by transcriptional or post-transcriptional control. Those 
circuits respond to the presence or absence of different small molecule 
inputs (often antibiotics). They can be layered to yield more intricate 
functions, even though it remains difficult to predict the behaviour of 
complex combinations. Introducing feedback loops in such circuits 
allows the design of systems showing hysteretic signal integration 
[35] or bimodal switch characteristics [36]. Rinaudo et al. [37] have 
engineered a ‘universal’ RNAi-based Boolean logic evaluator in which 
the molecular endogenous inputs are encoded by small interfering 
RNAs (siRNAs). The system can make decisions with up to five logic 
variables and uses computer-designed siRNA molecules for minimal 
crosstalk within the network. This synthetic ‘switchboard’ could 
be engineered in cells to respond to different environmental and 
intracellular variables (pH, light, metabolic state, insulin concentration, 
etc.) [38], making it a powerful tool for biomedical applications, both 
diagnostic and constructive.
Another logic circuit, the memory latch or toggle switch, was 
initially designed in E. coli [29] by combining two repressors, each of 
which controlled the other’s expression. Kramer et al. [39] developed the 
PIPON/EON-based epigenetic toggle switch in Chinese hamster ovary 
cells where transient administration of one of two alternate antibiotics 
switched the system between two meta-stable transgene expression 
states. In other words, the cells ‘remembered’ their exposure to one 
drug until the memory was reset (‘erased’) by treatment with the other. 
These circuits are particularly useful to program mammalian processes 
with binary characteristics such as differentiation or apoptosis. This 
transcriptional switch was later improved and used in living mice [40], 
demonstrating its potential for precise long-term protein delivery in 
the absence of a sustained input, a critical feature when long term 
drug administration is potentially toxic or expensive.
Recently, Levskaya et al. [41] designed a light-inducible control 
system that can be used to sculpt mammalian cell shape. The circuit, 
based on an engineered, plant-derived light-sensitive protein and a 
reversible protein-protein interaction, recruits specific target proteins 
to the membrane. When the target protein in question is a modified 
activator of cytoskeletal organization, as it was in the paper, a beam of 
light can direct the formation of a lamellipodium. Such light-sensitive 
response elements could, in principle, be used in tissue engineering 
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for the controlled activation of various cellular processes in a spatio-
temporal manner. This is especially true in vitro, where access by light 
is easy, but may also be useful in some surface locations in vivo.
Tigges et al. [42] have adapted a synthetic oscillator design 
first demonstrated in bacteria [30] to develop robust and tuneable 
oscillations in mammalian cells. Coupling a positive feedback loop and 
a time-delayed negative feedback loop, this synthetic circuit showed 
autonomous and self-sustained oscillating gene expression. Another 
semi-synthetic oscillating genetic circuit features independent tuning 
of the amplitude, damping rate and oscillation frequency in human cells 
[43]. Such circuits provide insight into the complex mechanisms and 
perturbations that control dynamics in natural biological systems like 
circadian clocks. They can be implemented in systems where periodic 
synthesis and release of output molecules are needed and could provide 
sophisticated kinetic control for delivery of therapeutic agents in vivo.
Greber et al. [44] constructed a synthetic genetic network with 
band-pass detection characteristics; output expression is ‘off’ where 
there is no signal, ‘on’ across a window of low concentrations of input 
but ‘off’ again when the input concentration is high. Such a system is 
very interesting from the point of view of tissue engineering because it 
can be used for spatial patterning. If, for example, a signalling molecule 
is produced from one source and diffuses to create a gradient, the 
responsive gene will be ‘on’ in a halo around that source, demarcating 
a definite zone of tissue (Figure 2). If the responsive gene were itself 
a second, less diffusible, signalling molecule capable of driving 
another band-pass circuit (responsive only to this second molecule), 
a second layer of finer pattern would be added. Such systems could be 
combined to create highly complex predictable patterns. Another way 
of creating complex pattern would be coupling oscillator and band-
pass to control transgene expression. The well-known ‘somite clock’ 
that divides paraxial mesoderm into a series of blocks (the pre-pattern 
for vertebrae) is effectively a coupling of a band-pass system with an 
oscillator, with the additional feature that, once a band of tissues has 
decided to respond, it becomes a new source for the signal. 
Engineering cell-cell communication in E. coli, exploiting 
molecules used by various bacterial species for quorum sensing, has 
allowed multicellular quorum-sensing networks to detect population 
and to regulate it automatically by controlling cell death [45]. Basu et al. 
[46] also programmed multicellular populations to form patterns from 
an initially undifferentiated lawn, where ‘receiver’ cells differentiate on 
detection of a signal gradient synthesized by ‘sender’ cells. Building on 
prokaryote cell-cell communication designs, Weber et al. [47] fused 
bacterial quorum-sensing receptors with eukaryotic elements and 
constructed a signalling network consisting of human sender cells 
and CHO receiver cells with L-arginine as the signalling molecule. In 
principle, these signalling systems can operate in three-dimensions 
(3D), regulating cell density in the volume of an artificial tissue, so that 
the tissue can maintain itself in the face of attrition. 
We expect this list of mammalian bio-parts to grow rapidly in the 
coming years as other elegant prokaryotic designs (genetic counter 
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Figure 2: Synthetic band-pass filters as potential patterning elements. (a) depicts the architecture of the system built by Greber & Fussenegger [44], which is based 
on two separate pathways that can each inhibit the production of the output molecule. The top pathway, on its own a high-pass filter, makes molecule A to repress 
the production of output molecule unless tetracycline (tet) is present at high enough concentrations to inhibit production of A. The bottom pathway, a low-pass filter, 
includes an extra inverting step so that in the absence of tet, B1 is made and represses the production of B2 so there is no B2 to repress the output (the promoters of 
B2 and the output are ‘on’ unless repressed, the promoters of A and B1 are off unless activated). When tet is present, B1 is repressed and B2 is made. B2 is a less 
potent repressor of the output than is A, so that there is a window of tet concentration that suppresses A enough to allow some production of output and represses B1 
enough that some B2 is made, but not enough to completely suppress the output either. (b) The circuit therefore allows production of significant output over a narrow 
band of tet concentration. (c) If tet (or some other signalling molecule in an appropriately modified version of the circuit) were present in a gradient from one source, 
the band-pass filter would result in the production of the output in a halo around that source. (d) If the output were itself a signal that diffused less rapidly, and a second 
band-pass circuit responsive to this signal were present, another layer of detail would be added to the pattern. In this way, synthetic circuits could pattern tissues and, 
in principle, control location-dependent differentiation of cells.
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[48], edge detection program [49], synchronized genetic clock [50], 
etc.) will in all probability be adapted to the mammalian chassis. 
It is important to note that, as in other areas of engineering, 
modules-of-modules are likely to become important building blocks in 
construction: for example, transistors are ‘components’ at a low level, 
while fixed arrangements of transistors (in an integrated circuit) can be 
considered ‘basic components’ at higher level, and fixed arrangements 
of integrated circuits (e.g. data servers) can be considered ‘basic 
components’ at another level still. The ‘BioBricks’ available so far 
are basic DNA parts (promoters, protein-coding domains, etc.) or 
combinations of parts (logic gates, signal senders, etc.). Weber et 
al. [47] have considered making larger-scale parts available on the 
BioBrick registry: the so-called ‘CytoBricks’ are well-characterized 
mammalian cell lines with stably integrated synthetic networks. 
Applying this building blocks concept to yet other scales, we may 
envisage engineering whole tissue parts [24] or even organ parts (intra- 
or extra-corporeally).
Application area 1: biosynthesis and controlled release of 
therapeutic molecules
One of the most surprising results to emerge from studies of stem 
cell-assisted regeneration is that many grafted stem cells seem to assist 
the regeneration of damaged host tissues not by directly giving rise to 
new replacement parts but by secreting factors that induce endogenous 
cells to repair the tissue [51,52]. Given concerns about the safety of 
introducing multi- and pluripotent cells into a human host (with 
attendant risk of tumour formation [53]), there is much interest in 
identifying the factors involved and applying them without transferring 
stem cells as well. There is a problem, though, that these molecules are 
likely to be proteins that will not be absorbed intact if given orally, and 
long-term treatments will be required. 
One way of circumventing these problems in delivering large-
molecule, regeneration-promoting therapeutics such as proteins to the 
inside of the body is to have them synthesized by cells already inside, at 
the right place. The rate of this synthesis can then be controlled either 
by medically-applied small molecules (drugs that pass easily through 
the gut or skin) or, in more advanced designs, by feedback loops 
designed into the synthetic system.
The idea of controlling a synthetic circuit embedded into the 
body by externally-applied small molecules has been demonstrated 
in a proof-of-principle experiment by Gitzinger et al. [54], who 
constructed a transdermally-controllable transcription system in 
mammalian cells using the apple-derived metabolite phloretin as a 
non-toxic trigger. This synthetic, phloretin-adjustable control element 
was able to adjust target gene expression reversibly in transgenic cells 
that had been implanted into mice, with the phloretin applied as a skin 
lotion. Another example of control by small molecules is the vitamin H 
(biotin)-triggered genetic switch [55]. 
Light can also be used to control transgene expression in mammalian 
cells. Ye et al. [56] created a synthetic light-inducible transgene 
expression device by connecting the photopigment melanopsin to the 
Nuclear Factor of Activated T cells (NFAT) pathway for controlling 
specific gene expression. In their engineered cells, illumination caused 
the expression of a variant of the human glycoprotein secreted alkaline 
phosphatase that displays potent glucose modulating characteristics. 
When the device was implanted transdermally in mice, transgene 
expression was regulated through direct illumination and was able to 
attenuate glycaemic excursions in type II diabetes.
The ability of synthetic biologists to engineer systems that feature 
closed-loop feedback control creates the potential for homeostasis to 
control the concentration of a target molecule, be it a drug or, even 
more usefully, a clinically-relevant outcome. A vivid illustration of this 
approach has been provided by Kemmer et al. [57], who constructed 
a synthetic system to control blood urate levels in animals that could 
not do this for themselves. Elevated urate causes the painful human 
condition, gout. The synthetic network, constructed in mouse cells, 
monitors urate levels in the blood and uses this signal to control 
expression of urate oxidase, an enzyme that degrades urate (Figure 3). 
The synthetic circuit was tested in urate oxidase–deficient mice and 
was shown to be effective. 
None of these demonstrations address regenerative medicine 
directly, but they do illustrate the potential of the synthetic approach. 
Consider, for example, a variant of the urate system that, instead of 
controlling urate oxidase in response to fluctuating blood urate levels, 
synthesized insulin in response to fluctuating blood glucose. If it 
worked well enough, such a synthetic system (which could in principle 
be placed in any cell type, not just pancreatic β cells) could make 
regeneration of a pancreas damaged by type I diab etes unnecessary. 
In this type of application, synthetic biology would be an alternative to, 
rather than a means of, tissue regeneration.
Application area 2: production of improved scaffolds for 
tissue engineering
Cell behaviour and shape are influenced strongly by the constitution 
and morphology of the extracellular matrix (ECM). Traditional tissue 
engineering has therefore included much effort in the production of 
carefully-engineered matrices, or ‘scaffolds’, to guide the growth and 
behaviour of engrafted cells to make a tissue. Synthetic 3D extracellular 
microenvironments that mimic the structure and functions of the 
ECM have already been developed [58], but synthetic biology holds 
tremendous potential for improving these matrices and making them 
structurally programmable. 
Self-assembling peptide matrices form scaffolds that resemble 
cyto-architectures of tissues [59]. As in other fields of synthetic biology, 
these scaffolds are assemblies of known elements that can be considered 
building blocks [60]. They can incorporate different functional 
motifs to suit particular applications. Their molecular structures 
mUTS
urate
urate oxidase
+
+
+
promoter mUTS binding
site
Figure 3: A synthetic circuit built by Kemmer et al. [57], that uses negative 
feedback to control the concentration of free urate. When no urate is present, 
the repressor mUTS efficiently suppresses the transcription of urate oxidase. 
When urate is present, it inhibits mUTS, allowing transcription of urate oxidase 
to proceed. The enzyme oxidizes (removes) urate. The system as a whole 
therefore works as a homeostat, keeping urate to low levels.
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are repeats of alternative hydrophilic and hydrophobic amino acids 
that spontaneously form β-sheets. Due to their intermolecular ionic 
interactions, those β-sheets can in turn be packed together under 
physiological conditions in a chequer-board-like fashion to form 
regular, high-density matrices where cells can be grown homogenously. 
Unlike common, natural biomaterials, the peptide scaffolds are pure 
and do not elicit inflammatory reactions in animals [61, 62].
Hydrogels are flexible polymer matrices with a high water content: 
they can be engineered to include synthetic biology-derived parts 
to form interactive biohybrid materials for cell growth and tissue 
regeneration. Biological building blocks derived from proteins and 
DNA can be used for the construction of ‘smart’ hydrogels that are 
responsive to different stimuli. Those hydrogel structures have been 
extensively reviewed elsewhere ([63] for review) and we will give here 
only a brief overview.
DNA-based hydrogels can be engineered by crosslinking DNA 
to synthetic polymers such as polyacrylamide so that DNA molecules 
form bonds between branches of polymer. If complementary ssDNA 
oligonucleotides are applied to the gel, they spontaneously hybridize to 
the crosslinks and change the overall conformation of the gel. This can 
alter the gel’s stiffness [64], volume [65,66], or induce its dissolution 
[67].
A combination of drug-inducible, protein-releasing synthetic 
biological modules in cells and synthetic hydrogels can be used to 
achieve dissolution on command. Ehrbar et al. [68,69] engineered a 
smart hydrogel where increasing concentrations of antibiotic resulted 
in the dissolution of the gel and the release of an embedded growth 
factor in a time- and dose-dependent manner (Figure 4). Such 
controlled dissolution is valuable for tissue engineering, allowing an 
artificial scaffold to be replaced, over time, with a new natural one 
[70]. Hydrogels that respond to physiological stimuli have also been 
constructed by incorporating engineered biological receptors that 
undergo reversible conformational changes on binding substrates such 
as calcium ions [71], glucose [72] or ATP [73].
Interestingly, Christen et al. [74] designed a stimulus-responsive 
hydrogel based on the conformational rearrangement of a transcription 
factor. This is based on the TetR/TetO system that is commonly used 
for inducible gene-expression systems. Again, the effect of the inducing 
drug was to cause dissolution of the gel. In principle, other protein/
DNA operator combinations could respond specifically to very diverse 
compounds such as drugs, metabolites, pheromones, etc. If similar 
modules are combined within the same gel, the resulting system could 
deal with several inputs and reacts accordingly through multiple 
mechanical and structural outputs.
The development of smart hydrogels such as the ones described 
above is of great potential importance to regenerative medicine where 
they could be used as scaffolds, tissue barriers, drug-delivery agents, to 
encapsulate cells or to recruit a different subset of cells [75]. Another 
interesting feature of those hydrogels is their spontaneous assembly: 
no enzyme is required as the molecular information for assembly is 
encoded in the 3D structure of the peptides. These ECM substitutes 
can be injected and hydrogelation triggered subsequently in vivo [60].
There are, as yet, very few demonstrations of clinically-relevant 
tissue engineering that includes a synthetic biological component. One 
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Figure 4: Drug-sensing GyrB-based hydrogel for the inducible release of biopharmaceuticals. The gyrase subunit B (GyrB) was fused to a hexahistidine tag and 
dimerized by the antibiotic coumermycin. Mixing this protein with polyacrylamide (pAAm) functionalized with Ni2+-chelating nitrilotriacetic acid (NTA) resulted in the 
spontaneous formation of a hydrogel. Addition of novobiocin competitively prevented GyrB dimerization and triggered the dissolution of the hydrogel. This dissolu-
tion could be applied to trigger the release of a protein of interest (POI). Jakobus K, et al. [63] Synthetic mammalian gene networks as a blueprint for the design of 
interactive biohybrid materials. Chem Soc Rev, 2012 Reproduced by permission of The Royal Society of Chemistry.
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of the most spectacular was the combination of a cell encapsulation 
device with a synthetic biological circuit designed to achieve its 
controlled destruction. The application is in the field of animal fertility, 
specifically the insemination of cattle. As with natural mating, the 
success of artificial insemination depends on sperm being released into 
the female reproductive tract exactly when an egg has just been released 
into it. Kemmer et al. [76] encapsulated sperm in a cellulose-based 
capsule along with cells engineered to contain a hormone receptor that 
drove the synthesis of a cellulase. The hormone pulse accompanying 
ovulation caused synthesis of the cellulase, digestion of the cellulose 
capsule and consequent release of sperm onto the reproductive tract at 
just the right time.
Application area 3: regulation of stem cells
The area of regenerative medicine that is currently attracting most 
attention, from both scientists and public, is the construction of new 
tissue from stem cells. There are two ways in which synthetic biology 
could assist this effort even in the short term (more ways will probably 
be suggested as research progresses). These are (a) control of wild-type 
stem cells by a niche engineered using synthetic biological techniques, 
and (b) direct use of synthetic biology for stem cell ‘programming’.
The niche of a stem cell – that is, the environment provided 
by neighbouring cells, their secreted ligands and the extracellular 
matrix − is a very important regulator of stem cell behaviour [77]. In 
particular, being completely in the niche or just out of it can determine 
whether a cell just formed by stem cell division remains in self-
renewal or commits to differentiation [78]. The techniques for scaffold 
construction outlined in the last section can be used to construct 
synthetic environments favourable to stem cell growth, where lack of 
resemblance to natural niches is compensated by a better control over 
the different components and an ability to switch the niche ‘off’ (i.e. to 
promote differentiation only) on command [79]. Smart hydrogels can 
also facilitate stem cell encapsulation [80], 3D-culture morphology [81] 
and stem cell embedding [82] for in vivo use.
The ‘reprogramming’ of differentiated cells to become pluripotent 
again is a very important area of stem cell research, because it allows 
the use of isogenic cells with those of a patient in need and it avoids 
ethically-contentious use of human embryos. We note in passing that 
‘reprogramming’ is a very badly chosen word in this context, since 
the whole point is that the stem cells are shifted to a different (earlier) 
state in the natural human developmental programme. This state 
corresponds to that of the epiblast where cells can follow the human 
developmental programme a second time, according to the signals 
they now perceive. The phrase ‘reprogramming’, which fails to make 
the distinction between a ‘programme’ and a ‘state’ (a distinction made 
very clearly by Alan Turing at the dawn of computing in 1937), has 
now been broadly used and is sure to cause significant confusion in the 
era of synthetic biology, when reprogramming really will be performed.
There are two problems associated with induced pluripotential 
stem cells (iPSC): producing them in the first place and then controlling 
their differentiation. Since their discovery [83], iPSCs have been derived 
from adult cells with very low efficiency, by forcing the expression of 
four transcription factors (the ‘KMOS set’): KLF4, c-MYC, OCT4 and 
SOX2. Better control of the process is urgently needed and synthetic 
biology may make its first contribution simply as a research tool. 
For example, synthetic circuits could be used to provide a very fine 
temporal regulation of KMOS expression to allow researchers to 
analyze the optimal pattern for more reliable iPSC production [38]. 
Once iPSC production has been optimized, synthetic modules may be 
of great value in driving whole cascades of sequential gene expression 
to control cell fate with increased fidelity [84]. 
Application area 4: programming cells to construct designer 
tissues
One approach that could avoid the use of stem cells altogether 
would be to program cells directly to construct ‘designer tissues’. This 
would be a difficult and complex task but has the advantage that the 
tissues produced, either in vitro for use in extracorporeal life support 
machines or for transplantation to the body, or directly in situ, could be 
in arrangements that evolution has never produced.
A few years ago, one of the current authors published an outline 
of how this might be attempted [25]. The morphogenesis of natural 
embryonic tissues relies for the most part on about ten basic cell 
behaviours: proliferation, death, fusion, polarization, locomotion, 
chemotaxis, cell-cell adhesion, epithelial-to-mesenchymal transition, 
mesenchymal-to-epithelial transition and epithelial folding [85]. 
Each of these can be induced by the expression of a small number of 
regulatory proteins (often just one, given that the basic machinery 
is already available in a cell, waiting to be activated) [25]. It should 
therefore be possible to use control elements described in the overview 
of synthetic components near the beginning of this review to control 
the expression of these proteins and thereby to achieve ‘programmable 
morphogenesis’. The authors are currently working on precisely 
this project, as is a lab in the USA. The nature of the work means 
that clinically-relevant applications will be many years away but the 
flexibility and power of the approach may make it ultimately one of 
the most medically-significant applications of synthetic biological 
techniques.
Perspectives, challenges and dangers
Technical challenges: With recent advances in synthetic biology 
and the emergence of applied mammalian circuits as exemplified 
earlier, there is a pressing need for the expansion of the synthetic 
mammalian bio-parts toolbox, as well as continuing the increase in 
the level of complexity and sophistication of engineered networks. 
Fully autonomous systems with tunable and predictable behaviour are 
required if they are ever to be used in vivo, where they must be able 
to evolve or adapt to environmental conditions. With more complex 
systems come more technical issues: crosstalk between modules and 
with host network, cell death, mutations, time delay in gene expression, 
noise, etc.
Another problem to overcome is the integration of large complex 
networks in mammalian cell genomes. With technological advances in 
gene synthesis, the limiting technology is no longer the construction of 
complex circuits but their integration in the cell. There is little control 
in mammalian cells as to where transgenes are integrated and genomic 
location can greatly influence their expression through transcriptional 
perturbations, chromatin remodelling or DNA methylation. Thus, new 
technologies are needed for stable and reproducible integration: tools 
such as zinc-finger nucleases (used for site-specific integration) [86] 
or insulator elements (used as shields from location effects). Ideally, 
synthetic biologists should develop tools for repairing damaged 
elements of synthetic networks or returning systems to their initial 
structure after unexpected modifications.
As the complexity of synthetic systems increases, inputs from 
systems biology and computational biology are required to (i) identify 
new components from endogenous networks; (ii) predict systems 
behaviour by modelling and fine-tuning through in silico runs before 
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implementation; (iii) predict 3D development of structures and tissues; 
and (iv) visualize experimental 3D patterns.
A great number of technical challenges still need to be addressed in 
the field of tissue engineering. Complex features such as vasculature will 
need to be incorporated in engineered tissues where capillary networks 
are required for the exchange of nutrients and waste products. Ideally, 
engineered tissues should have regenerative powers to replace or repair 
damaged cells: stem cells, as well as elements of a healing response, 
should be incorporated. We are confident that synthetic biology can 
answer some of these issues, for example through the controlled spatio-
temporal delivery of molecules such as growth factors for angiogenesis 
or anti-inflammatory cytokines for improved healing. Synthetic 
biologists might also need to engineer cells that can detect host/
synthetic boundaries for the regulation of host cell infiltration into 
the graft (and vice versa). To do so, systems allowing recognition and 
regulation of the ‘synthetic-self’ are needed. Other systems could assist 
in the targeting and repair of injured or aberrant synthetic tissues, where 
synthetic cells could detect their potential abnormal state. A recent 
study [87] reported a synthetic regulatory circuit that senses expression 
levels of endogenous microRNAs and triggers apoptosis in engineered 
HeLa cells where expression levels matched a predetermined profile. 
This ‘cell-type classifier’ demonstrates the possibility of a programmed 
response to a complex cellular state and can assist in the control of 
post-implantation behaviour. A major concern that still needs to 
be addressed in both tissue engineering and synthetic biology is the 
durability of systems. It is important that engineered tissues last over 
years or decades in vivo and that engineered cells, if integrated in grafts, 
stay operational for as long a period. 
Perspective and dangers: This article is being written at, or rather 
just before, the dawn of the clinical application of synthetic biology and 
it is therefore full of prospects and predictions but very light on cases of 
use. Readers may, aware of the great distance between the small synthetic 
biology ‘toys’ that have been constructed so far and the applications we 
have outlined here, raise a note of scepticism and accuse the authors of 
unjustified hyperbole. The charge is reasonable; none of us can predict 
the future and the twentieth century contained many examples of 
apparently promising technologies that went nowhere (the flying car, 
the personal jet-pack), or were avoided due to a late appreciation of 
dangers (for example, nuclear-powered trains and cars). It is notable 
however, that many other technologies also began with a decade or two 
of amateurish and academic experimentation and proofs of principle, 
but then underwent an explosive and world-changing growth. A mere 
sixty years separates the Wright Brothers from the age of jet travel for 
all. Just thirty years took personal computing from the bedrooms of 
geeky kids who soldered together their own machines to the always-
connected, computer-in-the-pocket world of today. The progress of 
synthetic biology in general is being driven strongly by the need to 
replace fossil fuels and rare earth catalysts with plant- and microbe-
derived equivalents, and it is notable that developing countries seem to 
be most alert to these needs and so may move fastest. With the essential 
tools being made anyway, it seems to the authors very unlikely that 
synthetic biology will not become, during the next few decades, an 
essential feature of regenerative medicine. 
     New technologies can bring new dangers. The direct introduction 
of synthetic genetic modules into the human body carries obvious 
dangers that the modules may malfunction, for example by mutation 
or epigenetic modulation, and cause their cells to do something 
dangerous. This problem, similar to that faced by stem cell biologists, is 
more worrying than the familiar one of adverse drug reactions because 
the cells will be harder to remove. We expect, for this reason, the first 
applications of synthetic biology to be extracorporeal, and the first 
in situ examples to involve cells physically encapsulated in an easily-
removed container, “just in case”. It will probably be many years before 
such massively-engineered cells are allowed to roam freely around the 
body in routine Western medicine. 
The experience of the computer industry should alert 
biotechnologists to the possibility that they will have deal not just 
with accidental harm but also with individuals or organizations 
causing deliberate harm, for the processes of extortion, terrorism or 
simply adolescent showing-off. The use of conventional or synthetic 
virology to construct novel pathogens that infect humans will probably 
be restrained by the obvious danger that they may infect anyone 
including the perpetrator and his comrades. If, though, one group of 
people begins to contain a significant number of individuals who carry 
novel synthetic DNA sequences not present in the rest of humanity, 
and especially if this group of people happen to be mainly the wealthy 
and powerful members of the world’s economically and militarily-
dominant countries, that constraint may no long apply: it may be 
possible to design biological ‘malware’ (a literal virus) that can attack 
only those people. It may be sensible to consider these risks now, 
before we have become too committed to any particular technology, 
and to design defensively. The use of exactly the same components to 
construct everything may be a weakness in the face of potential attacks, 
and biological engineering may need to include significant diversity 
(the same arguments apply to the application of synthetic biology in 
the agricultural and bio-energy sectors). It may also be sensible, for 
reasons of self-interest as well as normal humanitarian ethics, to make 
advances in clinical synthetic biology available world-wide and not just 
to the rich, for if every nation has people whose lives have been saved 
by this technology and who carry its modules inside them, there will be 
no “us and them” to support the logic of an asymmetric attack.
These issues, and other more nebulous ones about human identity 
in an age of biological engineering, demand that scientists involved 
engage properly with ethicists, philosophers and the public. A failure 
to do so over the question of genetically-modified food resulted in a 
public backlash that has excluded the technology almost completely 
from the European Union. It would be a terrible mistake if we were to 
allow this to happen to synthetic biology too.
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